A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis - Trial NCT06073119
Access comprehensive clinical trial information for NCT06073119 through Pure Global AI's free database. This Phase 2 trial is sponsored by Sanofi and is currently Recruiting. The study focuses on Psoriasis. Target enrollment is 207 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sanofi
Timeline & Enrollment
Phase 2
Oct 26, 2023
Apr 24, 2025
Primary Outcome
Proportion of participants with a 75% or greater PASI score (Psoriasis Area and Severity Index score) improvement (reduction) from baseline (PASI75) at week 12
Summary
This is a Phase 2, international, multicenter, randomized, double-blind, placebo-controlled,
 dose-ranging, 12-week study. It is designed to assess the therapeutic dose, efficacy, and
 safety of treatment with SAR441566 in male and female adults with moderate to severe plaque
 psoriasis. Study details include a screening period (4 weeks and not less than 11 days before
 Day 1), a treatment period (12 weeks ± 3 days) and a post-treatment period (safety follow-up)
 (2 weeks ± 3 days). The total number of study visits will be 7.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06073119
Non-Device Trial